886371-24-0

Basic information

• Product Name: C-(3-Trifluoromethyl-pyridin-2-yl)-methylamine
• Synonyms: C-(3-Trifluoromethyl-pyridin-2-yl)-methylamine;(3-(Trifluoromethyl)pyridin-2-yl)methanamine;(3-(trifluoromethyl)pyridin-2-yl)methanamine hydrochloride;[3-(Trifluoromethyl)pyridin-2-yl]methylamine;2-(Aminomethyl)-3-(trifluoromethyl)pyridine;coMpound with oxalic acid;C-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)METHYLAMINE HCL;2-PyridineMethanaMine,3-(trifluoroMethyl)-
• CAS NO: 886371-24-0
• Molecular Formula: C₇H₇F₃N₂
• Molecular Weight: 176.1391
• Product Categories: Building Blocks;Pyridine
• Mol File: 886371-24-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 187.3 °C at 760 mmHg
• Flash Point: 67.1 °C
• Appearance: /
• Density: 1.293 g/cm³
• Vapor Pressure: 0.634mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.25±0.39(Predicted)
• CAS DataBase Reference: C-(3-Trifluoromethyl-pyridin-2-yl)-methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: C-(3-Trifluoromethyl-pyridin-2-yl)-methylamine(886371-24-0)
• EPA Substance Registry System: C-(3-Trifluoromethyl-pyridin-2-yl)-methylamine(886371-24-0)

Safety Data

• Hazardous Substances Data: 886371-24-0(Hazardous Substances Data)

Usage

Uses

3-(Trifluoromethyl)-2-pyridinemethanamine is used in the discovery of 4-Amino-8-quinoline carboxamides as novel, submicromolar inhibitors of NAD-hydrolyzing enzyme CD38.

InChI:InChI=1/C7H7F3N2/c8-7(9,10)5-2-1-3-12-6(5)4-11/h1-3H,4,11H2

Upstream product

• 406933-21-9 2-cyano-3-(trifluoromethyl)pyridine 

Downstream Products

• 1396734-59-0 C₁₂H₁₅F₃N₂O₂ 

Relevant articles and documents

Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists

A series of orexin receptor antagonists was synthesized based on a substituted piperidine scaffold. Through traditional medicinal chemistry structure-activity relationships (SAR), installation of various groups at the 3-6-positions of the piperidine led to modest enhancement in receptor selectivity. Compounds were profiled in vivo for plasma and brain levels in order to identify candidates suitable for efficacy in a model of drug addiction.